Kunihiko Umekita

Prof. Dr. Kunihiko Umekita

University of Miyazaki Hospital, Miyazaki, Japan
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in Viruses
Verified
Journal Article
Open access
PDF file
TKTakeshi Kawaguchi
Takeshi Kawaguchi
KUKunihiko Umekita
Kunihiko Umekita
AYAtsushi Yamanaka
Atsushi Yamanaka
SHSeiichiro Hara
Seiichiro Hara
TYTetsuro Yamaguchi
Tetsuro Yamaguchi
AOAkihiko Okayama
Akihiko Okayama
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging viral hemorrhagic fever in China, Korea, and Japan. To date, no standardized treatment protocol for SFTS has been established. Corticosteroids (CS) may be administered to patients with SFTS and hemophagocytic syndrome, but its effectiveness and safety are still debatable. We conducted a retrospective case series review at four medical facilities in Miyazaki, Japan. Based on the medical records, clinical data, including the patients background, symptoms, physical findings, laboratory data at initial presentation, treatment, and outcome, were compared between the CS-treated and the non-CS-treated group. A total of 47 patients with confirmed SFTS in each hospital were enrolled in this study; there were 14 fatal cases and 33 nonfatal cases. The case fatality ratio was 29.8%. After adjusting patients’ background by propensity score matching, the case fatality ratio was higher (p = 0.04) and complications of secondary infections, including invasive pulmonary aspergillosis, tended to be more frequent (p = 0.07) in the CS-treated group than in the non-CS-treated group. These data suggested that administration of CS to patients with SFTS should be carefully considered.

24 November 2011 in Rheumatology
Verified
Journal Article
Open access
PDF file
KUKunihiko Umekita
Kunihiko Umekita
YKYumi Kaneko
Yumi Kaneko
KYKenji Yorita
Kenji Yorita
YHYayoi Hashiba
Yayoi Hashiba
MMMotohiro Matsuda
Motohiro Matsuda
AOAkira Okayama
Akira Okayama
Sir, Recent reports of IgG4-related disease have described various organ involvement [1, 2]. Chronic inflammation can affect lacrimal glands, salivary glands, the thyroid, lung, pancreas, kidney and prostate. The concept includes Mikulicz's disease, Riedel's thyroiditis, pulmonary fibrosis, pulmonary pseudotumour, autoimmune pancreatitis, a part of tubulointerstitial nephritis and chronic prostatitis. It is important to note that these lesions can occur at different times and sites. The disease is clinically characterized by elevated serum IgG4 concentration and infiltration of abundant IgG4-positive plasma cells in the various tissues, mainly exocrine tissue [3, 4]. Mikulicz's disease presents with enlargement of the lacrimal or salivary glands with infiltrate IgG4-positive plasma cells. Numerous IgG4-positive plasma cells were characteristically observed in pancreatic tissue with autoimmune pancreatitis. In IgG4-related disease, mass-forming lesions (pseudotumours) that consist of lymphoplasmacytic infiltrates and sclerosis, such as retroperitoneal sclerosis, are observed [5]. Fluorodeoxyglucose PET (FDG-PET)/CT is a very useful tool for evaluation of multiple organ involvement in IgG4-related disease [6, 7]. Here, we would like to report a case of arthropathy with infiltration of IgG4-positive plasma cells in synovial tissue without any other organ involvement. In the present case, we have not detected any organ involvement or mass-forming lesion on FDG-PET/CT except for the joints.

14 October 2013 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
KUKunihiko Umekita
Kunihiko Umekita
THToshihiko Hidaka
Toshihiko Hidaka
SMShunichi Miyauchi
Shunichi Miyauchi
SUShiro Ueno
Shiro Ueno
KKKazuyoshi Kubo
Kazuyoshi Kubo
AOAkihiko Okayama
Akihiko Okayama
Objective: To investigate the response to and safety of anti–tumor necrosis factor (anti‐TNF) therapy in human T lymphotropic virus type I (HTLV‐I)–positive patients with rheumatoid arthritis (RA).Methods: Therapeutic response was evaluated in 10 HTLV‐I–positive and 20 HTLV‐I–negative patients with RA (sex and age matched) at 3 months after the beginning of anti‐TNF therapy using the European League Against Rheumatism improvement criteria. As secondary end points, the discontinuation rate of anti‐TNF therapy and its safety, especially the development of adult T cell leukemia (ATL), were evaluated over a 2‐year period.Results: Significantly higher baseline levels of C‐reactive protein (CRP) were observed in HTLV‐I–positive patients than in HTLV‐I–negative patients (P = 0.0003). The response rate to anti‐TNF therapy was lower in HTLV‐I–positive patients than in HTLV‐I–negative patients. The median CRP level, erythrocyte sedimentation rate, and Disease Activity Score in 28 joints at 3 months after anti‐TNF treatment in HTLV‐I–positive patients were significantly higher than in HTLV‐I–negative patients (P = 0.003, P = 0.03, and P = 0.003, respectively). The discontinuation rate due to insufficient response was significantly higher in HTLV‐I–positive patients than in HTLV‐I–negative patients (P = 0.013). During the 2‐year observation period, no patients developed ATL.Conclusion: These data suggest that HTLV‐I–positive patients with RA had higher inflammation and greater resistance to anti‐TNF treatment than HTLV‐I–negative patients. Further study is necessary to determine whether HTLV‐I infection should be measured when anti‐TNF agents are administered to patients with RA, especially in areas were HTLV‐I is endemic.

15 July 2018 in Internal Medicine
Verified
Journal Article
Open access
PDF file
ITIchiro Takajo
Ichiro Takajo
KUKunihiko Umekita
Kunihiko Umekita
YIYoshihiko Ikei
Yoshihiko Ikei
KOKoichi Oshima
Koichi Oshima
AOAkihiko Okayama
Akihiko Okayama
The patient was a 74-year-old Japanese woman with rheumatoid arthritis (RA) who developed generalized lymphadenopathy with elevated levels of lactase dehydrogenase (LD), and soluble IL-2 receptor (sIL-2R). She was found to be positive for anti-human T-cell leukemia virus type 1 (HTLV-1) antibodies. Her symptoms and laboratory abnormalities spontaneously regressed after the cessation of methotrexate (MTX), suggesting that she had an MTX-associated lymphoproliferative disorder; however, her lymphadenopathy appeared again approximately 14 months later with LD and sIL-2R elevation. A histopathological analysis and Southern blotting of a lymph node biopsy specimen for HTLV-1 provirus supported the diagnosis of adult T-cell leukemia/lymphoma (ATL) (lymphoma type). These data confirmed that an HTLV-1 positive RA patient may develop ATL.

7 June 2021 in Viruses
Verified
Journal Article
Open access
PDF file
KIKosho Iwao
Kosho Iwao
TKTakeshi Kawaguchi
Takeshi Kawaguchi
MKMasatoshi Kimura
Masatoshi Kimura
CIChihiro Iwao
Chihiro Iwao
MRMao Rikitake
Mao Rikitake
KUKunihiko Umekita
Kunihiko Umekita
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tickborne infectious disease in China, Korea, and Japan caused by the SFTS virus (SFTSV). SFTS has a high mortality rate due to multiorgan failure. Recently, there are several reports on SFTS patients with mycosis. Here, we report a middle-aged Japanese SFTS patient with invasive pulmonary aspergillosis (IPA) revealed by an autopsy. A 61-year-old man with hypertension working in forestry was bitten by a tick and developed fever, diarrhea, and anorexia in 2 days. On day 4, consciousness disorder was appearing, and the patient was transferred to the University of Miyazaki Hospital. A blood test showed leukocytopenia, thrombocytopenia, as well as elevated levels of alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, and creatine kinase. The SFTSV gene was detected in serum using a reverse-transcription polymerase chain reaction. On day 5, respiratory failure appeared and progressed rapidly, and on day 7, the patient died. An autopsy was performed that revealed hemophagocytosis in the bone marrow and bleeding of several organs. IPA was observed in lung specimens. SFTSV infection may be a risk factor for developing IPA. Early diagnosis and treatment of IPA may be important in patients with SFTS.

22 December 2022 in Ticks and Tick-borne Diseases
Verified
Journal Article
Open access
CKChiho Kaneko
Chiho Kaneko
HMHirohisa Mekata
Hirohisa Mekata
KUKazumi Umeki
Kazumi Umeki
PSPutu Eka Sudaryatma
Putu Eka Sudaryatma
TITakao Irie
Takao Irie
TOTamaki Okabayashi
Tamaki Okabayashi
Severe fever with thrombocytopenia syndrome (SFTS) is a fatal emerging tick-borne zoonotic disease caused by the SFTS virus (SFTSV). SFTSV infection in humans and companion animals is a matter of concern in endemic areas. Various wild animals are involved in the transmission cycle of SFTSV with vector ticks. Because the home range of medium-sized wild mammals commonly overlaps with humans' living spheres, this study aimed to reveal the endemicity of SFTSV in such mammals. This study investigated the prevalence of antibodies against SFTSV and viral RNA in medium-sized wild mammals in Miyazaki Prefecture, Japan where human cases have been most frequently reported in Japan and performed a phylogenetic analysis to compare the detected SFTSV with those previously reported. Forty-three of 63 (68%) Japanese badgers (Meles anakuma) and 12 of 53 (23%) Japanese raccoon dogs (Nyctereutes procyonoides viverrinus) had antibodies against SFTSV. Japanese marten (n = 1), weasels (n = 4), and Japanese red fox (n = 1) were negative. Two of 63 (3%) badgers tested positive for SFTSV RNA, whereas the other species were negative. Phylogenetic analysis of the partial nucleotide sequence of SFTSV revealed that viral RNA detected from badgers exhibited 99.8% to 100% similarity to SFTSV, as previously reported in humans, cat, and ticks in the study area. This study demonstrated high seropositivity of antibodies in medium-sized wild mammals and suggested that SFTSV could be shared among these mammals, humans, and companion animals in endemic areas.